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Abstract Mutations in TAR DNA-binding protein 43
(TDP-43) are associated with familial forms of amyotrophic
lateral sclerosis (ALS), while wild-type TDP-43 is a patho-
logical hallmark of patients with sporadic ALS and
frontotemporal lobar degeneration (FTLD). Various in vitro
and in vivo studies have also demonstrated toxicity of both
mutant and wild-type TDP-43 to neuronal cells. To study the
potential additional toxicity incurred by mutant TDP-43 in
vivo, we generated mutant human TDP-43 (p.M337V)
transgenic mouse lines driven by the Thy-1.2 promoter
(Mt-TAR) and compared them in the same experimental
setting to the disease phenotype observed in wild-type
TDP-43 transgenic lines (Wt-TAR) expressing comparable
TDP-43 levels. Overexpression of mutant TDP-43 leads to a
worsened dose-dependent disease phenotype in terms of
motor dysfunction, neurodegeneration, gliosis, and develop-
ment of ubiquitin and phosphorylated TDP-43 pathology.
Furthermore, we show that cellular aggregate formation or
accumulation of TDP-43 C-terminal fragments (CTFs) are
not primarily responsible for development of the observed
disease phenotype in both mutant and wild-type TDP-43
mice.
Keywords Amyotrophic lateral sclerosis . Frontotemporal
lobar degeneration . TARDBP . Transgenic mice . Ubiquitin
Introduction
TAR DNA-binding protein 43 (TDP-43) is the major path-
ological inclusion protein involved in the pathogenesis of
amyotrophic lateral sclerosis (ALS) and frontotemporal lo-
bar degeneration (FTLD) linked to TDP-43 pathology
(FTLD-TDP), providing a molecular link that put these
disorders in a common ALS-FTLD disease spectrum [1–3].
ALS is the most common adult-onset form of motor neuron
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disease and is characterized by a degeneration of cortical
motor neurons and anterior horn cells of the spinal cord.
FTLD-TDP, on the other hand, is the most common patholog-
ical subtype of FTLD [1, 2], the latter only being preceded in
prevalence by Alzheimer’s disease [3, 4]. Numerous causal
missense mutations in the TDP-43 gene (TARDBP) have been
reported in patients with ALS (AD&FTLD Mutation
Database; http://www.molgen.ua.ac.be/Admutations/) [5–8].
TDP-43 is a highly conserved, ribonuclear protein with two
RNA recognition motifs (RRM1 and RRM2) and a glycine-
rich C-terminal domain that mediates protein–protein interac-
tions [9]. Nearly all of the TDP-43 mutations are local-
ized within the glycine-rich domain of TDP-43
indicating a high importance for this domain in disease
development [7]. Several functions of TDP-43 have
been described such as a role in transcription, RNA
splicing, microRNA biogenesis and development [10].
In addition, comprehensive studies aimed at identifying
RNA-binding targets for TDP-43 found a multitude of
target RNAs including transcripts of genes involved in RNA
metabolism, synaptic function, and central nervous system
(CNS) development [11]. However, it remains unclear which
of these functions, if any, are hampered by aberrant TDP-43
and trigger disease development [12].
TDP-43 pathology in ALS and FTLD-TDP patients is
characterized by abnormal protein processing including
ubiquitination, phosphorylation, and proteolysis generat-
ing C-terminal fragments (CTFs) [1, 2, 13]. The abnor-
mal TDP-43 species are sequestered in both cytoplasmic
and nuclear protein aggregates, which are invariably
associated with substantial depletion of nuclear full-
length TDP-43, a phenomenon called “nuclear clearing”
[1, 2]. Recent studies have indicated that the TDP-43 C-
terminus contains a “prion-like” domain that makes full-
length TDP-43 or its CTFs aggregation prone [14, 15].
Although toxicity of CTFs and aggregate formation has
been shown before [16, 17], it is currently unknown
whether these TDP-43 species are mechanistically linked
to neurodegeneration or constitute a secondary event in
the disease cascade. Furthermore, additional toxicity in-
curred by TARDBP mutations compared to wild-type
TDP-43 in the development of ALS-FTLD diseases also
needs further clarification. Several animal models
overexpressing either mutant or wild-type TDP-43 have
been reported (Table 2) to develop a highly similar
ALS-FTLD-like phenotype [18–28]. To investigate the
potential additional toxicity incurred bymutant TDP-43 on the
integrity of neuronal cells, we developed various germline
transgenic mouse lines overexpressing human TDP-43
containing the methionine-to-valine substitution (p.M337V)
occurring in familial ALS patients [6]. Transgene expression
was driven by the murine Thy-1.2 promoter and trans-
genic lines were chosen to have comparable TDP-43
levels as previously reported by us for wild-type TDP-
43 mice [24]. Compared to wild-type TDP-43 mice,
overexpression of mutant TDP-43 leads to a worsened
dose-dependent ALS-FTLD-like phenotype in terms of
motor dysfunction and lethality, neurodegeneration, and
gliosis as well as development of phosphorylated TDP-43
cytoplasmic granules. We also show that accumulation
of CTFs, together with formation of aggregates do not
seem to be associated with the development of the
observed ALS-FTLD-like phenotype.
Material and Methods
Generation of Mutant (p.M337V) Human TDP-43
Overexpression Mice
Mice overexpressing mutant human TDP-43 were developed
using TARDBP cDNA amplified from a human cDNA library
and cloned into a Thy-1.2 expression vector (mTUB, QPS
JSW Life Sciences GmbH; www.jsw.lifesciences.com)
containing a modified murine Thy-1.2 promoter [24].
The p.M337V missense mutation was introduced by
standard Polymerase Chain Reaction (PCR) mutagenesis
(QuikChange®, Stratagene) and the sequence was veri-
fied by Sanger sequencing. The expression vector was
subsequently microinjected into pronuclear oocytes of
Bl6/SJL mice by the Yale Transgenic Mouse Service
Facility (New Haven, CT, USA). Offspringwere genotyped
and 11 transgenic pups carried the transgene. Founder mice were
backcrossed to C57Bl6/J up to five generations to establish
stable transgenic mouse lines. Furthermore, hemizygous cross-
breedings were performed to obtain homozygous mutant TDP-
43 overexpressing mice. Zygosity was determined by Multiplex
Amplicon Quantification (MAQ, Multiplicom) assays and
PCR (PCR primers available on request). Homozygous ex-
pression levels were confirmed by semiquantitative real-time
PCR (qRT-PCR) on brain tissue of 2-week-old mice. All
animal experiments were approved by the University of
Antwerp Ethics Committee and conducted according to the
guidelines of the Federation of European Laboratory Animal
Science Associations (FELASA) and the EU Directive 2010/
63/EU for animal experiments.
Gait Analysis
Motor coordination and balance were assessed by acceler-
ating rotarod and footprint analysis, as described previously
[24]. Briefly, accelerating rotarod (Rota-Rod Treadmill;
Med Associates Inc.) was performed for three subsequent
runs and repeated every month. Gradual acceleration of the
rotating rod ranged from 2.5 to 25 rpm and 3.5 to 35 rpm,
with a maximum observation time of 5 min. Time spent on
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the rod was automatically recorded by interrupting a
photobeam on the rotarod floor.
Limb motor function was assessed by footprint analysis
where fore- and hindpaws were dipped in red and black
nontoxic paints, respectively. Subsequently, mice were
allowed to walk down a narrow runway (50 cm long, 7 cm
wide, and flanked by 10 cm high walls) with a white paper
covering the floor. Paw position and stride width and length
as well as the paw progression angle (PPA) were measured
and compared to non-transgenic (Ntg) littermates.
Tissue Harvesting and Processing
Brains were harvested, weighed, and cut midsagittally
according to standard protocol [29]. Right hemispheres were
snap frozen in liquid nitrogen and stored at −80 °C for
subsequent mRNA and protein analysis. Left hemispheres
were fixed in 2 % paraformaldehyde (PFA) for 18–20 h and
prepared for paraffin embedding. Spinal cords were
processed similarly as described for brain. Cerebral and
lumbar parts of the spinal cord were cut and fixed in 4 %
glutaraldehyde for 4 h for electron microscopy analysis.
Semiquantitative Real-time PCR
To determine the expression levels of human and mouse
TDP-43, total RNA was isolated from murine brain using
the RiboPure™ kit followed by a DNase treatment (TURBO
DNase Kit; both Ambion). First-strand cDNA was synthe-
sized using the SuperScript® III First-Strand Synthesis
System (Life Technologies) using random hexamer primers.
Expression was measured using TaqMan® MGB assays
(human and mouse TDP-43) designed with File Builder
software (Applied Biosystems) or SYBR Green technology
(cathepsin D and caspase-3) on an ABI ViiA™ 7 Real-Time
PCR System (Applied Biosystems). Quantification of tran-
script levels was achieved with glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) and β-actin as housekeeping con-
trols (primer and probe sequences available on request), as
described previously [30]. Each sample was measured in
duplicate and at least two independent experiments were
performed.
Immunoblotting
Proteins from brain tissue were prepared as low-salt and 2 %
sodium dodecyl sulfate (SDS) fractions using cell lysis buffer
(CLB; 10 mM HEPES, 10 mM NaCl, 1 mM KH2PO4, 5 mM
NaHCO3, 5 mM ethylenediaminetetraacetic acid (EDTA),
1 mM CaCl2, 0.5 mM MgCl2, 10× volume/weight (V/wt))
followed by radioimmunoprecipitation assay (RIPA) buffer
supplemented with 2 % SDS (5× V/wt), as described previously
[24]. All reported buffers were supplemented with protease
(complete protease inhibitor cocktail, Roche) and phosphatase
(PhosphoSTOP, Roche) inhibitors.
Protein content of low-salt fractions was determined with a
bicinchoninic acid colorimetric assay (Perbio Science N.V.).
Equal protein amounts were loaded and separated on 10 %
Nupage® Bis–Tris gels (Life Technologies) and electroblotted
onto a polyvinylidene difluoride membrane (Hybond P,
PVDF; Amersham Biosciences). After blotting, membranes
were blocked in 5 % skimmed milk in phosphate-buffered
saline (PBS) containing 0.1 % Tween® 20 (Merck).
Membranes were probed with a range of primary antibodies
listed in Table S1. Immunodetection was achieved using
horseradish peroxidase (HRP)-conjugated secondary anti-
bodies and an ECL Plus™ chemiluminescent detection sys-
tem (GE Healthcare). Bands were quantified on a Kodak
Imaging Station 440 (Eastman Kodak) and quantitative data
were normalized to GAPDH for low-salt fractions (Meridian
Life Science) or lamin A/C for 2 % SDS fractions (clone N-
18, Santa Cruz Biotechnology), as described earlier [24].
Histology and Immunohistochemistry
For each specimen, 4-μm thick sections were cut using an
automated HM355 Microm rotary microtome (Microm
International). Classical histochemistry was performed
according to standard protocols [31]. For immunohistochemis-
try (IHC), sections were deparaffinized, rehydrated, pretreated
with citrate buffer to enhance immunoreactivity, and developed
using 3,3′-diaminobenzidine (DAB). Primary antibodies used
for IHC are listed in Table S1. Sections were counterstainedwith
hematoxylin. Images were taken on an Axioskop 50 light mi-
croscope (Zeiss) equipped with a CCDUC30 camera (Olympus
Inc.). Double-labeling immunofluorescence was performed on
brain sections using a TDP-43 non-species-specific (Proteintech
Group) or a phosphorylated TDP-43 (CosmoBio; pS409/pS410
or pS403/404) specific antibody together with a TIA-1 (Santa
Cruz Biotechnology) or monoclonal ubiquitin (Life
Technologies) antibody, and visualized with secondary anti-
bodies conjugated to Alexa Fluor® 488 or Alexa Fluor® 594
(Life Technologies). 4′,6-Diamidino-2-phenylindole (DAPI;
Bio-Rad) was used as a nuclear counterstain. Images were taken
on a LSM700 confocalmicroscope (Zeiss). For quantification of
gliosis, 40× images were taken in the cortical layer Vof the brain
and the anterior horn of the spinal cord from Ntg (n=3) andMt-
TAR6/6 (n=3) mice. Immunoreactive astrocytes and glial cells
were counted manually and normalized to the area.
Electron Microscopy
Ultrastructural microscopy was performed on cerebral and lum-
bar regions of the spinal cord from transgenic and Ntg control
animals. Tissue was fixed in 4 % buffered glutaraldehyde for
4 h, and 2 % osmium tetraoxide before embedding and
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processing according to standard protocols [31, 32]. Sections
were contrasted with routine uranyl acetate and lead citrate and
analyzed by a Philips CM10 electron microscope equipped with
a goniometric coordinator as reported previously [31].
Statistical Analysis
All experiments were performed in duplicate and repeat-
ed at least two times with results reported as mean ±
standard deviation (SD). P values for description of statistical
significance of differences were calculated by two-tailed
Student’s t tests if not mentioned otherwise. P<0.05 was
considered significant.
Results
Mutant (p.M337V) TDP-43 Expression is Comparable
to Transgene Levels in Wild-Type TDP-43
Overexpression Mice
We previously demonstrated that overexpression of wild-
type human TDP-43 under control of a neuronal murine
Thy-1.2 promoter leads to a dose-dependent ALS-FTLD-
like motor phenotype in two independent mouse lines
(TAR4/4 and TAR6/6; hereafter called Wt-TAR4/4 and
Wt-TAR6/6) [24]. To compare potential additional toxicity
of mutant TDP-43 with wild-type TDP-43, we generated
multiple mouse lines for mutant (p.M337V) TDP-43 using
the same promoter (Fig. 1a). The choice of the promoter for
both mutant and wild-type lines was driven by two impor-
tant requirements. First, because TDP-43 aggregates are
majorly present in neurons, the use of a neuronal Thy-1.2
promoter was preferred for these experiments as it drives
expression preferentially in neurons. Second, the Thy-1.2
promoter becomes active approximately 1 week after birth
[33] that reduces the risk of interfering with essential func-
tions of TDP-43 during embryonic development [5].
Eleven transgenic founders for mutant p.M337V TDP-43
mice were generated that showed germline transmission of
mutant TDP-43. To match expression levels with those of
the previously reported hemi- and homozygous wild-type
TDP-43 mice [24], different homozygous and double hemi-
zygous mutant TDP-43 mice were generated. Two lines
(Mt-TAR5 and Mt-TAR6) were selected that showed 0.34-
and 0.88-fold mutant TDP-43 expression compared to en-
dogenous transcript levels analyzed by qRT-PCR on brain
tissue. In addition, homozygous Mt-TAR5/5, double hemi-
zygous Mt-TAR5/6, and homozygous Mt-TAR6/6 were
generated that showed expected expression levels (Fig. 1b,
Fig. S2a). Transgene doses measured in Wt-TAR4 and Wt-
TAR4/4 mice were highly comparable to Mt-TAR6 and Mt-
TAR6/6 mice, respectively, and TDP-43 levels in Wt-
TAR6/6 mice were similar to Mt-TAR5/6 mice (Table 1).
The equivalent expression levels between both mouse models
allowed us to make direct comparisons concerning pathoge-
nicity of wild-type versus mutant TDP-43 overexpression
with respect to the disease phenotype and TDP-43 pathology.
Dose-dependent Motor Phenotype in Mutant TDP-43 Mice
is Worsened Compared to Wild-Type TDP-43 Mice
Mutant TDP-43 mice were morphologically indistinguish-
able from their Ntg littermates at birth. Starting at an age
of ≈12 days, however, the highest expressing Mt-TAR6/6
mice developed an abnormal hindlimb reflex when
suspended by their tails, whereas Ntg littermates extended
their hindlimbs (Fig. 1c). This atypical clasping reflex was
also reported in wild-type TDP-43 mice [24] and is consid-
ered as one of the earliest symptoms of loss of motor control
in different ALS mouse models [34]. The severity of the
disease phenotype advanced rapidly for Mt-TAR6/6 mice
exhibiting a closed body posture, muscle twitches, and
reduced mobility at ≈15 days, which was followed by com-
plete paralysis and death within the next 1–2 days (Fig. 1e
and g; Movie S1). In addition, Mt-TAR6/6 mice showed
severe postnatal growth retardation, including a significant
reduction in body weight (54 %; P<0.001; Fig. S1a) and
brain weight (22 %; P<0.001; Fig. S1b) compared to Ntg
littermates. Interestingly, the motor phenotype in Mt-
TAR6/6 mice is highly comparable to that observed in Wt-
TAR4/4 mice. Despite nearly identical transgene expression
levels, Wt-TAR4/4 mice consistently showed a mildly de-
layed age of onset for clasping (≈14 days), paralysis (starting
at 22 days), and death (25–26 days) [24] (Table 1 and Fig. 1g).
A similar disease phenotype was also present in the second
highest expressing double-hemizygousMt-TAR5/6 mice. The
average age of onset as well as disease severity and progres-
sion, however, were highly variable. This was demonstrated
by several Mt-TAR5/6 mice dying between 1 and 3 months of
age, whereas other mice could age up to 17 months.
Nevertheless, even in these so-called escapees, abnormal
hindlimb reflex (Fig. 1c) and mild paralysis of the hindlimbs
with reduced mobility were present. To confirm these obser-
vations, we performed motor coordination and gait analyses
for Mt-TAR5/6 mice. On the accelerated rotarod test, a signif-
icant impairment in motor coordination and balance of Mt-
TAR5/6 mice was observed at 9 months of age (n=7; P=
0.037; Fig. S3b) that worsened with aging, and at an age of
15 months, mice showed a 36 % decrease in running time
compared to Ntg littermates (n=7; P=0.003; data not shown).
A footprint analysis for gait also showed an increased paw
progression angle (PPA) of the hindlimbs in contrast to Ntg
littermates (Fig. S3a; P=0.003). No significant differences
were found in stride length, although a decreasing trend was
observed in Mt-TAR5/6 mice (data not shown).
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The third highest expressing hemizygous Mt-TAR6 mice
lived up to 24 months, although they acquired an abnormal
hindlimb reflex at 12 months (Fig. 1c and g). Rotarod data
showed impairment in motor function beginning at
13 months of age (n=14; P=0.002; Fig. S3b). These
changes were also progressive as the same colony of mice
showed a maximum decrease of 36 % in running time at an
age of 16 months compared to Ntg littermates (n=14; P=
0.004). Despite having an equivalent TDP-43 expression,
the age of onset for gait abnormalities was accelerated in
Mt-TAR6 mice compared to Wt-TAR4 mice (Fig. S3b). Not
surprisingly, Mt-TAR6 mice also showed phenotypic vari-
ability with a minority of mice (~5 % of the entire colony),
developing complete paralysis of the hindlimbs where ani-
mals were unable to hold their body off the ground and use
their forelimbs to drag themselves forward (Fig. 1f, Movie
S2). In this subset of mice, hindlimb paralysis also ranged
from 3 to 14 months, indicating variability in both age of
onset and disease progression in these lines. In contrast, no
clinical phenotype has been observed for low-expressing
Mt-TAR5 and Mt-TAR5/5 mice analyzed up to 18–
22 months of age. Furthermore, no differences in motor
Fig. 1 Overexpression of mutant human TDP-43 leads to a dose-
dependent motor phenotype. a Modified Thy-1.2 expression vector
used to generate mutant (p.M337V) human TDP-43 (hTDP-43) trans-
genic mice. b TARDBP mRNA expression levels measured in brain by
qRT-PCR for the different mutant TDP-43 (Mt-TAR) mouse lines. Mt-
TAR6/6 expression levels were comparable to those measured in wild-
type TDP-43 mice (Wt-TAR4/4 and Wt-TAR4) as described earlier. c
Overexpression of mutant TDP-43 induced an abnormal hindlimb
reflex (arrows) at variable ages dependent on the TDP-43 dose that
was absent in non-transgenic (Ntg) mice and Mt-TAR5/5 mice express-
ing a low TDP-43 dose. d TDP-43 dose for both mutant (Mt-
TAR6/6, n=8; Mt-TAR5/6, n=7; Mt-TAR6, n=12) and wild-type
(Wt-TAR4/4, n=6; Wt-TAR4, n=8; Wt-TAR6/6, n=4) TDP-43
mice showed a log–log correlation with the age of onset or the
age where the abnormal hindlimb reflex was first noticed (R2=
0.97). e Typical example of an end-stage paralysis in Mt-TAR6/6
mice (Movie S1). f About 5 % of end-stage hemizygous Mt-
TAR6 mice developed severe paralysis of the hindlimbs and
acquired a swimming gait. g Kaplan–Meier analysis for different
mutant and wild-type TDP-43 mice revealing a reduced lifespan
for transgenic mice compared to Ntg littermates. Homozygous
mutant TDP-43 mice show higher mortality compared to wild-
type TDP-43 mice, which is reflected by an average survival of
17 days for Mt-TAR6/6 compared to 24 days for Wt-TAR4/4
mice (Mt-TAR6/6, n=29; Wt-TAR4/4, n=49). Double hemizygous
Mt-TAR5/6 mice have an average survival of 9.3 months com-
pared to 16.4 and 16.6 months for Mt-TAR6 and Wt-TAR4 mice,
respectively (Ntg, n=69; Mt-TAR6, n=72; Wt-TAR4, n=46; Mt-
TAR5/6, n=31). [24]
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performance on rotarod were observed for Mt-TAR5/5 mice
up to an age of 20 months. Taking average age of onsets for
the abnormal hindlimb reflex, the correlation of mutant
TDP-43 levels in Mt-TAR6/6, Mt-TAR5/6 and Mt-TAR6
mice is best illustrated by a log–log regression model (cor-
relation coefficient R2=0.97; Fig. 1d, red curve), which is
highly similar to the correlation of wild-type TDP-43 levels
measured in Wt-TAR4/4, Wt-TAR4, and Wt-TAR6/6 mice
(correlation coefficient R2=0.98; Fig. 1d, blue curve).
Interestingly, a high degree of variability in age of death was
also observed in our second and third highest expressing Wt-
TAR6/6 and Wt-TAR4 mice [24] (Table 1), with Wt-TAR6/6
dying between 1 and 19 months and some Wt-TAR4 mice
living more than 26 months. While some degree of variability
is routinely observed in even inbred mouse strains [35], this
high degree of variability in phenotype at lower TDP-43 doses
suggests involvement of genetic or epigenetic modifying fac-
tors influencing levels of TDP-43. To test this hypothesis, we
measured TDP-43 levels in the second highest expressing Mt-
TAR5/6 mice that had an early or a later age of onset. We
demonstrated small but significantly decreased levels of TDP-
43 in mice having a later age of onset (P=0.032; Fig. S2c).
Our data also suggested that although mutant TDP-43 mice
displayed a comparable disease phenotype compared to Wt-
TDP-43 mice, overexpression of mutant TDP-43 appeared to
have an accelerating effect on the age of onset and disease
progression. We, therefore, studied whether mutant TDP-43
overexpression could lower the dose of endogenous TDP-43
by autoregulatory mechanisms as suggested recently [36].
Consistent with several studies [18, 25–28], both mutant and
wild-type TDP-43 overexpression induced a transgene dose-
dependent decrease in endogenous TDP-43 transcripts. The
decrease noted in Mt-TAR6/6 and Mt-TAR5/6 lines was 24 %
(P=0.005) and 18% (P=0.055), respectively, compared to Ntg
littermates (Fig. S2b). This reduction in endogenous TDP-43
expression was not more than the observed decrease of 26 %
(P=0.004) in similarly expressing Wt-TAR4/4 mice,
suggesting that pathogenic mutant TDP-43 does not act by
decreasing endogenous TDP-43 levels.
Comparable Selective Vulnerability of Neuronal
Subpopulations and Dose-dependent Gliosis in Mutant
and Wild-Type TDP-43 Mice
Although the Thy-1.2 promoter drives expression in virtu-
ally all neuronal cells of the brain and spinal cord, selective
vulnerability was observed for specific neuronal subpopula-
tions including cortical layer V motor neurons, spinal ante-
rior horn motor neurons, CA regions of the hippocampus,
and thalamic neurons. This selective vulnerability was high-
ly reminiscent of wild-type TDP-43 mice in which TDP-43
expression was driven by the same promoter [24]. In regions
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regions of the hippocampus, more drastic pathology was
observed for mutant TDP-43 mice. For instance, the highest
expressing Mt-TAR6/6 mice showed severe neuronal loss in
all CA regions of the hippocampus with complete oblitera-
tion of CA3 and CA4 fields, while CA1 and CA2 fields
were reduced to a single layer of neurons. In contrast,
equally expressing Wt-TAR4/4 mice showed complete
obliteration of only the CA4 field, whereas CA1 and CA2
fields were relatively unaffected (Fig. S4a).
Interestingly, these pathological changes were accompa-
nied by a 1.4-fold increase in caspase-3 expression levels in
both Mt-TAR6/6 and Wt-TAR4/4 mice compared to Ntg
mice (Fig. S5; P=0.017 and P=0.008, respectively). These
data were confirmed by increased cleaved caspase-3 immu-
noreactivity for both cortical (Fig. S5) and spinal cord (data
not shown) neurons in end-stage mutant and wild-type TDP-
43 mice. Consistent with the fact that neurodegeneration is
regularly accompanied by strong astroglial and microglial
pathology, we also identified dose-dependent astrogliosis
and microgliosis in mutant TDP-43 mice in the same re-
gions that were affected by neuronal loss (Fig. 2a, b and Fig.
S4b, c). Compared to Ntg mice, a statistically significant two-
to fivefold increase in glial fibrillary acidic protein (GFAP)-
positive astrocytes and Iba-1-positive microglial cells was
observed in the highest expressing Mt-TAR6/6 mice in both
motor cortex (P≤0.001 for both) and spinal cord (P=0.003 for
both) (Fig. 2c, d). Interestingly, compared to Wt-TAR4/4
mice, Mt-TAR6/6 mice also showed a ≈50 % increased
astroglial reactivity in the motor cortex (Fig. 2c; P=0.034).
Severe astrogliosis and microgliosis were also present in the
hippocampus of end-stage Mt-TAR5/6 and Mt-TAR6/6 mice
compared to control littermates, which is in accordance with
the amount of neurodegeneration found in the different CA
regions (Fig. S4b, c). These data suggest that the observed
astrogliosis and microgliosis in TDP-43 mice are both dose-
and mutation-dependent (Fig. 2c, d).
Accumulation of Ubiquitinated Proteins and Eosinophilic
Mitochondrial Aggregates in Mutant and Wild-Type
TDP-43 Mice
TDP-43 is processed and degraded by both autophagy and
the ubiquitin–proteasome system (UPS) and also acts as a
maintenance factor of the autophagy system [37, 38].
Interestingly, increased lysosomal cysteine protease cathep-
sin D expression levels (1.5- and twofold increase) and
immunostaining were observed in both brain and spinal cord
of Mt-TAR6/6 and Wt-TAR4/4 mice compared to age-
matched controls (Fig. S6a). However, utilizing both IHC
and immunoblot analysis of total brain lysates, no signifi-
cant alterations in either LC3 (microtubule-associated pro-
tein light chain 3) or p62 (autophagy receptor protein) were
observed for Mt-TAR6/6 and Wt-TAR4/4 mice. These data
suggest that overexpression of TDP-43 does not lead to an
impaired turnover of autophagosomal vesicles.
Ubiquitinated neuronal inclusions are a pathological hall-
mark of several neurodegenerative disorders including ALS
and FTLD-TDP [39]. To determine whether overexpression
of mutant TDP-43 recapitulates the formation of these ac-
cumulations in our mutant TDP-43 mice, we examined brain
and spinal cord sections of Mt-TAR6/6 and Mt-TAR5/6
mice and compared them to the pathology found in Wt-
TAR4/4 mice as well as to ALS-FTLD patients. Ubiquitin
IHC revealed an abnormal increase in cytoplasmic ubiquitin
staining within motor neurons of the cortical layer V of Mt-
TAR6/6 and Wt-TAR4/4 mice, which was absent in Ntg
mice (Fig. 3a). Mildly increased ubiquitin immunoreactivity
was also observed in other brain regions such as the hippo-
campus, pons, and Purkinje cells of the cerebellum. The
intensity of the cytoplasmic ubiquitin immunoreactivity ob-
served in Mt-TAR5/6 mice was highly variable, whereby
mice having severe phenotype at younger ages developed
stronger ubiquitin immunoreactivity compared to select
mice that had milder phenotype at older ages. These data
suggest that the diffuse neuronal ubiquitin immunoreactivity
in TDP-43 mice is intimately associated with the disease
progression.
In addition to the diffuse neuronal ubiquitin immunore-
activity, circumscribed ubiquitin-positive inclusions were
also observed in cortical layer V neurons of several Mt-
TAR5/6, Mt-TAR6/6, and WT-TAR4/4 mice but were ab-
sent in Ntg controls (Fig. 3b1–3). On several occasions,
more than one inclusion was found in a single neuron.
Spinal motor neurons also showed a diffuse ubiquitin
staining in the cytoplasm together with an accumulation of
ubiquitinated proteins for all analyzed mouse lines.
However, in contrast to the brain, no clear ubiquitinated
inclusions were observed in spinal cord sections. In addi-
tion, not all analyzed end-stage Mt-TAR6/6 mice developed
ubiquitinated inclusions in contrast to the diffuse ubiquitin
immunoreactivity that was always present in mice that had a
severe phenotype (see above). Furthermore, few ≈1-month-
old Mt-TAR5/6 mice showed more abundant and larger
ubiquitin-positive accumulations in the motor cortex com-
pared to younger and higher transgene-expressing Mt-
TAR6/6 mice (Fig. 3b1–2). Of all TDP-43 mice, end-stage
Wt-TAR4/4 mice showed the largest load of ubiquitinated
inclusions in the motor cortex, and interestingly, Wt-
TAR4/4 mice lived longer than the Mt-TAR6/6 mice
(Fig. 3b 3). Taken together, these results suggest that devel-
opment of inclusions is not essential for TDP-43-led pathol-
ogy in TDP-43 transgenic mice.
Mt-TAR6/6 as well as Wt-TAR4/4 mice also presented
with different inclusions that were ubiquitin-negative. These
large, amorphous, eosinophilic inclusions were observed in
the cytoplasm of the anterior horn cells of the spinal cord
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and coincided with development of severe pathology
(Fig. 3d, arrows). In addition, the eosinophilic inclusions
were also observed, although to a lesser extent, in cortical
layer V (Fig. 3c, arrows), thalamus, pons, and the Purkinje
cell layer of the cerebellum. No differences were identified
for the eosinophilic aggregate load or size in the highest
expressing Mt-TAR6/6 mice compared to equal expressing
Wt-TAR4/4 mice (Fig. 3c, d). Further analysis of the nature
of these cytoplasmic inclusions by electron microscopy for
the same spinal cord regions showed that they coincided
with abnormal accumulations of proliferating mitochondria
(Fig. 3e–h), as was also recently shown in other TDP-43
models [19, 25, 28]. The majority of mitochondria in both
mutant and wild-type TDP-43 mice had an abnormal ultra-
structural appearance, comprising deformed cristae and fis-
sion deficits. Interestingly, despite the high load of abnormal
Fig. 2 Dose-dependent gliosis in mutant TDP-43 mice. a GFAP
immunohistochemistry of cortical layer V and spinal cord of Ntg, Mt-
TAR6/6, Mt-TAR5/6, and Wt-TAR4/4 mice showing TDP-43 dose-
dependent astrogliosis. b Similarly, Iba1 immunoreactivity showed a
dose-dependent microgliosis in Mt-TAR6/6, Mt-TAR5/6, and Wt-
TAR4/4 mice compared to Ntg littermates. c Highly increased number
of astrocytes in brain and spinal cord of Mt-TAR6/6 and Wt-TAR4/4
mice compared to Ntg littermates. d Significantly increased number of
activated microglia in brain and spinal cord of Mt-TAR6/6 and WT-
TAR4/4 mice compared to Ntg littermates. Overall, mutant TDP-43
induced a more pronounced gliosis than wild-type TDP-43
overexpression. Data are represented as mean ± SD. Scale bars
50 μm. *P<0.05; **P<0.01; ***P<0.001
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mitochondria present in Mt-TAR6/6 mice, they never
exhibited the same load of mitochondria as observed in
Wt-TAR4/4 mice (Fig. 3e–h).
Consistent with the abnormal accumulation of ubiquitinated
proteins in both mutant and wild-type TDP-43 mice, we also
observed increased cytoplasmic reactivity to ubiquilin 2
(UBQLN2) that regulates degradation of ubiquitinated
proteins. Interestingly, mutations in UBQLN2 were found to
cause chromosome X-linked ALS and ALS/dementia [40].
Although no UBQLN2-positive aggregates were observed in
TDP-43 mice, UBQLN2 accumulation was detected in both
cortical layer V and spinal motor neurons of Mt-TAR6/6 mice
(Fig. S6b), and at least for cortical layer V, the staining patterns
were appreciably stronger compared to Wt-TAR4/4 mice (Fig.
Fig. 3 Accumulation of ubiquitinated proteins and eosinophilic mito-
chondrial aggregates in cortical and spinal neurons of transgenic TDP-
43 mice. a Ubiquitin pathology in layer V of the motor cortex of both
Mt-TAR6/6 and Wt-TAR4/4 mice, which was absent in Ntg mice.
Scale bars 50 μm. b In addition, ubiquitinated cytoplasmic inclusions
could be observed in (1) Mt-TAR5/6, (2) Mt-TAR6/6 and (3) Wt-
TAR4/4 mice. Scale bars 10 μm. Hematoxylin and eosin (H&E)
staining of brain and spinal cord showed accumulation of eosinophilic
structures (arrows) in large motor neurons of c cortical layer V and d
spinal cord of end-stage Mt-TAR6/6, Mt-TAR5/6, and Wt-TAR4/4
mice, which were absent in Ntg control mice. Scale bars 20 μm. e–h
Ultrastructural analysis of lumbar spinal cord demonstrated abnormal
accumulations of mitochondria of various shapes (insets) in f–g Mt-
TAR6/6 and h Wt-TAR4/4 mice compared to e Ntg controls. g Clus-
tered mitochondria were deformed and enlarged with disorganized
cristae in Mt-TAR6/6 mice. f and h Insets in the upper right corner
show a higher magnification of the boxed region. Scale bars 2 μm
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S6b). Our results suggest that degradation of ubiquitinated
proteins is disturbed in mutant and wild-type TDP-43 mice
and more so in the mutant mice.
TDP-43 Pathological Alterations in Mutant TDP-43
Overexpression Mice
TDP-43 is suggested to be a principal component of ubiquitin-
positive inclusions in ALS and FTLD-TDP [1, 2]. Using
different TDP-43 antibodies (Table S1), the primary localiza-
tion of TDP-43 was observed within neuronal nuclei of the
brain and spinal cord of mutant and wild-type TDP-43 mice,
as was the case for endogenous TDP-43 in Ntg mice (Fig. 4a,
b). Nuclear TDP-43 was absent from apoptotic and dying
neurons (Fig. 4a, double arrowhead) [12, 41]. Interestingly, a
small subset of cortical neurons of Mt-TAR6/6 and Mt-
TAR5/6 mice also showed diffuse cytoplasmic TDP-43
staining, which was more evident with a human-specific
TDP-43 antibody (Fig. 4b, asterisks). Such diffuse cytoplas-
mic TDP-43 staining was also present in spinal motor neurons
of Mt-TAR6/6 and Mt-TAR5/6 mice and many neurons also
showed a strong reduction in nuclear TDP-43 immunoreac-
tivity (Fig. 4c, arrowheads). Remarkable nuclear TDP-43
clearing was observed in the spinal cord of Mt-TAR6/6 mice
using a TDP-43 non-species-specific antibody (Fig. 4c, inset).
Utilizing a phosphorylated TDP-43 (pS403/pS404) specific
antibody, small granular accumulations were also identified in
the cytoplasm of cortical layer V neurons of both mutant and
wild-type TDP-43 mice but were most abundant in the highest
expressing Mt-TAR6/6 mice (Fig. 4d, arrowheads). Such
accumulations were extremely rare in spinal motor neurons
and absent in both cortical and spinal neurons of Ntg controls.
More interestingly, neither TDP-43 nor phosphorylated TDP-
43 immunostaining substantially colocalized with ubiquitin
inclusions for mutant TDP-43 mice as has also been shown
earlier for wild-type TDP-43 mice [24] (Fig. S7a–b). These
findings suggest that an entirely different subset of proteins is
ubiquitinated in TDP-43-mediated neurodegeneration in
TDP-43 transgenic mice.
Because aggregation of FUS and TDP-43 has been
suggested to proceed through the stress granule pathway
[42–44], we analyzed any recruitment of stress granules in
Fig. 4 Redistribution of nuclear TDP-43 and formation of phosphor-
ylated (pS403/404) TDP-43 accumulations in the cortex of mutant
TDP-43 mice. Immunohistochemistry for a total and b–c human
TDP-43 of Mt-TAR6/6, Mt-TAR5/6, and Wt-TAR4/4 mice indicated
that TDP-43 resides mainly in the nucleus of a–b cortical and c spinal
motor neurons. However, nuclear TDP-43 was absent in a apoptotic
neurons (double arrowhead). b Using a human-specific TDP-43 anti-
body, some neurons of Mt-TAR6/6 and Mt-TAR5/6 mice also showed
diffuse reactivity in the cytoplasm (asterisks). Human TDP-43
reactivity was absent in Ntg control mice. c The presence of cytoplas-
mic TDP-43 staining was often accompanied by reduced nuclear TDP-
43 immunoreactivity in spinal motor neurons (arrowheads). Nuclear
clearing and diffuse cytoplasmic staining were also observed using a
non-species-specific antibody (inset). d Small granular structures im-
munoreactive for phosphorylated (pS403/404) TDP-43 were present
within the cytoplasm of cortical neurons of Mt-TAR6/6 and Wt-TAR4/
4 mice and, to a lesser extent, in Mt-TAR5/6 mice (arrowheads). Scale
bars 10 μm
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cytoplasmic phosphorylated TDP-43 granules. Utilizing a
well-known marker for stress granules (T cell intracellular
antigen-1, TIA-1), no clear colocalization was observed with
the pS403/404-positive granules in the cortex of Mt-TAR6/6
mice (Fig. S7c). This data is in line with previous results,
where in contrast to spinal cord regions, no colocalization of
stress granule markers was present in TDP-43 inclusions in
brains of FTLD-TDP and ALS-TDP patients [45]. As Mt-
TAR6/6 mice do not show phosphorylated TDP-43 granules
in the spinal cord, recruitment in stress granules could not be
analyzed here.
Pathological TDP-43 is also known to be cleaved into
25–35-kDa CTFs in the cortex, but not in the spinal cord of
FTLD and ALS patients [1, 46, 47]. To similarly character-
ize the pathogenic potential of TDP-43 CTFs, we performed
immunoblotting on sequential brain extracts from different
disease stages of Mt-TAR6/6 mice and Wt-TAR4/4 mice.
Utilizing a non-species-specific TDP-43 antibody, we iden-
tified ≈35-kDa fragments in soluble low-salt fractions al-
ready at disease onset, which decreased gradually with
disease progression (Fig. 5a). Compared to disease onset,
end-stage Mt-TAR6/6 mice showed a significant decrease in
≈35-kDa CTFs up to 32 % (Fig. 5a; P=0.048) and was
highly comparable with a similar statistically significant
35 % decrease in Wt-TAR4/4 mice in the low-salt fractions
(Fig. 5a; P=0.034). The low-salt fraction generally repre-
sents the cytoplasmic fraction with presence of cytoplasmic
GAPDH and absence of nuclear lamin A/C proteins in this
fraction [24]. Analysis of the sequentially extracted brain
proteins in 2 % SDS fractions did not show notable differ-
ences in ≈35-kDa CTFs between disease onset and disease
end-stage for both Mt-TAR6/6 and Wt-TAR4/4 mice
(Fig. 5b). These data confirm earlier reports that the ≈35-
kDa TDP-43 CTFs might not be critical for TDP-43
proteinopathy [1, 24].
On the other hand, accumulation of 25-kDa CTFs asso-
ciated with disease severity was very remarkable for Wt-
TAR4/4 mice especially in the insoluble 2 % SDS fraction
(48 % increase; P=0.023) and confirms our earlier report
[24]. Interestingly, no significant difference in 25-kDa CTFs
was observed for disease progression in Mt-TAR6/6 mice,
and end-stage Mt-TAR6/6 mice showed 58 % lower levels
of 25-kDa CTFs, compared to end-stage Wt-TAR4/4 mice
(P=0.011). Although we cannot exclude the possibility that
toxicity incurred by mutant 25-kDa CTFs might be substan-
tially higher than by wild-type fragments, our data already
Fig. 5 Aberrant processing of TDP-43 in mutant TDP-43 mice. a–b
Immunoblot analysis of brain lysates of Mt-TAR6/6 and Wt-TAR4/4
mice using a non-species-specific TDP-43 antibody showed gradually
decreased 35-kDa C-terminal fragments (CTFs) with disease progres-
sion in a low-salt fractions. b No major differences in ≈35-kDa CTFs
were observed between disease onset and disease end stage in 2 % SDS
fractions. Accumulation of ≈25-kDa CTFs in 2 % SDS fractions was
more pronounced in Wt-TAR4/4 mice compared to Mt-TAR6/6 mice.
a–b Quantification indicated no significant difference in Mt-TAR6/6
mice for ≈25-kDa CTFs between disease onset and disease end-stage.
GAPDH and lamin A/C were used as a marker for low-salt and 2 %
SDS fractions, respectively. Data are represented as mean ± SD.
*P<0.05
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suggest that pathogenic mutations in TDP-43 do not induce
an appreciably increased accumulation of CTFs by in-
creased production or stability of these fragments in mice.
Discussion
TDP-43 plays a major role in the pathogenesis of ALS and
FTLD disorders characterized by TDP-43-positive neuropa-
thology. While wild-type TDP-43 is the key pathogenic
substrate in the majority of these ALS and FTLD patients,
mutant forms of TDP-43 can also drive ALS pathology in
those carrying a TARDBP missense mutation. To study the
mechanism(s) by which TDP-43 causes ALS and FTLD,
several mouse models expressing wild-type or mutant TDP-
43 have been generated [18–28]. Interestingly, wild-type
and mutant TDP-43 overexpressing mouse models show
striking similarities in disease phenotype including gait im-
pairment, neurodegeneration, and TDP-43misprocessing, mak-
ing it difficult to assess the relative contribution of mutated
TARDBP to disease development. To address these questions,
we established p.M337V human TDP-43 overexpressionmouse
models that expressed comparable TDP-43 levels to wild-type
human TDP-43 mice, driven by the same Thy-1.2 promoter
[24]. Thy-1.2 is active only after P8 and therefore avoids drastic
effects of TDP-43 expression during development or very early
postnatal stages [26, 48, 49]. Phenotypic, biochemical, and
pathological comparisons between mutant TDP-43 mouse lines
and similar transgenic wild-type TDP-43 lines, in the same
experimental setting, provided us with interesting conclusions
regarding differences and commonalities between mutant and
wild-type TDP-43-led pathology. First, compared to wild-type
TDP-43, mutant TDP-43 mice showed worsened disease as-
pects including motor dysfunction and neurodegeneration ac-
companied by gliosis. Although we have only studied the
p.M337V mutation, we presume that an increased toxic poten-
tial could be extrapolated to other TDP-43 mutations affecting
the terminal glycine-region of TDP-43.
Secondly, we show here that TDP-43-positive inclusions,
regularly observed in brain and spinal cord of ALS and
FTLD patients [50], are not a major disease feature in the
studied TDP-43 mouse models. This is in line with other
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reported TDP-43 models where TDP-43 inclusions were also
mostly absent (Table 2) [18, 20–22, 24, 25, 28]. Utilizing
phosphorylated TDP-43 antibodies, we did observe very few
cytoplasmic phosphorylated TDP-43 granules. Although for-
mation of phosphorylated TDP-43 granules did not correlate
with disease progression in TDP-43 mice, these granules were
more abundant in mutant TDP-43 compared to wild-type
TDP-43 mice. On the other hand, diffuse neuronal ubiquitin
immunoreactivity was the only neuronal marker that associ-
ated with disease progression in mutant TDP-43 mice. The
more characteristic ubiquitin-positive inclusions were less
pronounced in mutant TDP-43 mice compared to equally
expressing wild-type TDP-43 mice and did not seem to be
influenced by either the progression or severity of the disease
or disease-related mortality. These data all suggest that forma-
tion of TDP-43- or ubiquitin-positive inclusions is rather a late
event in disease pathogenesis. We cannot exclude, however,
the possibility that the occurrence of TDP-43 inclusions can
hasten disease pathogenesis and subsequently shorten disease
duration as has been observed in sporadic ALS patients [51].
Another characteristic of TDP-43 proteinopathy is the
accumulation of TDP-43 CTFs in specific brain regions of
FTLD and ALS patients, but not in spinal cord regions [46,
47]. Formation of CTFs in the brain was reported in several
TDP-43 overexpression models and was found to correlate
with disease progression [22, 24]. We showed here that
while both mutant and wild-type TDP-43 mice accumulated
25-kDa CTFs, their formation was significantly less pro-
nounced in mutant TDP-43 mice despite having a more
severe phenotype. Although formation of CTFs might have
an impact on disease pathogenesis [46, 52], our data suggest
that TDP-43 fragmentation is not a prerequisite for disease
development at least not in the studied TDP-43 mice.
Whether the lack of TDP-43-positive inclusions in our mu-
tant TDP-43 mice is due to the lower accumulation of TDP-
43 CTFs or due to the suggested requirement of a “second-
hit” remains unknown [53].
To conclude, we show here that compared to wild-type
TDP-43, mutant human TDP-43 expression in mice leads to
a worsened dose-dependent disease phenotype with respect
to motor dysfunctions, neurodegeneration, phosphorylated
TDP-43 pathology, and lethality. Our data also suggest that
TDP-43 CTFs or TDP-43 or ubiquitin-positive aggregates
are not a prerequisite for disease development in TDP-43
overexpressing mice.
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